High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma- 90Y-ibritumomab tiuxetan in combination with BEAM [carmustine, etoposide, cytarabine, melphalan] or BEAC [carmustine, etoposide, cytarabine, cyclophosphamide] to improve outcome for patients not in CR [complete response] after induction treatment.

Trial Profile

High-dose therapy with autologous stem cell support in first line treatment of mantle cell lymphoma- 90Y-ibritumomab tiuxetan in combination with BEAM [carmustine, etoposide, cytarabine, melphalan] or BEAC [carmustine, etoposide, cytarabine, cyclophosphamide] to improve outcome for patients not in CR [complete response] after induction treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Melphalan
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 May 2012 Actual patient number added 160 according to ClinicalTrials.gov.
    • 03 May 2012 Actual patient number added 160 according to ClinicalTrials.gov.
    • 03 May 2012 Actual end date (June 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top